Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TKT | P29401 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615786 | 0.84 | TRPV4 (0.53) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL317731 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL40545 | 0.79 | LOXL2 (0.53) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL29995657 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL91511 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL20376114 | 0.79 | IDO1 (0.43) | TRPV4IDO1PPARD | |
| SCHEMBL129948 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL345116 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL132198 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB | |
| SCHEMBL452178 | 0.79 | TRPV4 (0.52) | TRPV4DAOKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166177-A | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020070651-A1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-9884824-B2 | Methods of producing sulfilimine compounds | DOW AGROSCIENCES LLC (US) | 2018-02-06 | — | — | US | disclosed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | TRPV4 1747/4885DAO 542/4885KDM1A 625/4885 |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | TRPV4 3363/4885DAO 144/4885KDM1A 1275/4885 |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | TRPV4 4516/4885DAO 2793/4885KDM1A 3230/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | TRPV4 3734/4885DAO 260/4885KDM1A 1200/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | TRPV4 3721/4885DAO 305/4885KDM1A 1422/4885 |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | TRPV4 2304/4885DAO 933/4885KDM1A 591/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | TRPV4 2088/4885DAO 466/4885KDM1A 1671/4885 |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | TRPV4 2304/4885DAO 933/4885KDM1A 591/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | TRPV4 2304/4885DAO 933/4885KDM1A 591/4885 |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PDE4A, PDE4B, PDE12 | TRPV4 770/4885DAO 212/4885KDM1A 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.